Randomized comparative study on efficacy and safety of tacrolimus, prednisolone or placebo in ocular myasthenia gravis patients

Randomized comparative study on efficacy and safety of tacrolimus, prednisolone or placebo in ocular myasthenia gravis patients - Efficacy and safety of tacrolimus in ocular myasthenia gravis

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007679

Enrollment

Registered

2012-04-09

Start date

2012-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myasthenia gravis

Interventions

Administration of tacrolimus 3 mg/day Administration of prednisolone 5 mg/day anticholinesterases

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: ocular type myasthenia gravis patients

Exclusion criteria

Exclusion criteria: Patients disqualified by doctor in attendance with any reason

Design outcomes

Primary

Measure	Time frame
Total QMG scores of the ocular symptomes after 4 months	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026